Brepocitinib approval for dermatomyositis would be ‘highlight of the derm-rheum world’

DESTIN, Fla. — The anticipated FDA approval of brepocitinib signals an important shift in dermatomyositis management, according to a speaker at the Congress of Clinical Rheumatology East.“A true highlight of the derm-rheum world is that we finally will have an FDA-approved therapy that is modern, targeted and effective in both skin and muscle disease of dermatomyositis,” said